219 related articles for article (PubMed ID: 9351621)
1. Controlled trial of inhaled budesonide in patients with cystic fibrosis and chronic bronchopulmonary Psuedomonas aeruginosa infection.
Bisgaard H; Pedersen SS; Nielsen KG; Skov M; Laursen EM; Kronborg G; Reimert CM; Høiby N; Koch C
Am J Respir Crit Care Med; 1997 Oct; 156(4 Pt 1):1190-6. PubMed ID: 9351621
[TBL] [Abstract][Full Text] [Related]
2. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group.
Ramsey BW; Pepe MS; Quan JM; Otto KL; Montgomery AB; Williams-Warren J; Vasiljev-K M; Borowitz D; Bowman CM; Marshall BC; Marshall S; Smith AL
N Engl J Med; 1999 Jan; 340(1):23-30. PubMed ID: 9878641
[TBL] [Abstract][Full Text] [Related]
3. Once-daily budesonide inhalation powder (Pulmicort Turbuhaler) maintains pulmonary function and symptoms of asthmatic children previously receiving inhaled corticosteroids.
Shapiro GG; Mendelson LM; Pearlman DS
Ann Allergy Asthma Immunol; 2001 Jun; 86(6):633-40. PubMed ID: 11428735
[TBL] [Abstract][Full Text] [Related]
4. Once-daily budesonide via Turbuhaler improves symptoms in adults with persistent asthma.
Banov CH; Howland WC; Lumry WR
Ann Allergy Asthma Immunol; 2001 Jun; 86(6):627-32. PubMed ID: 11428734
[TBL] [Abstract][Full Text] [Related]
5. Multicenter randomized controlled trial of withdrawal of inhaled corticosteroids in cystic fibrosis.
Balfour-Lynn IM; Lees B; Hall P; Phillips G; Khan M; Flather M; Elborn JS;
Am J Respir Crit Care Med; 2006 Jun; 173(12):1356-62. PubMed ID: 16556691
[TBL] [Abstract][Full Text] [Related]
6. A phase 2 study of aztreonam lysine for inhalation to treat patients with cystic fibrosis and Pseudomonas aeruginosa infection.
Retsch-Bogart GZ; Burns JL; Otto KL; Liou TG; McCoy K; Oermann C; Gibson RL;
Pediatr Pulmonol; 2008 Jan; 43(1):47-58. PubMed ID: 18041081
[TBL] [Abstract][Full Text] [Related]
7. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial.
Saiman L; Marshall BC; Mayer-Hamblett N; Burns JL; Quittner AL; Cibene DA; Coquillette S; Fieberg AY; Accurso FJ; Campbell PW;
JAMA; 2003 Oct; 290(13):1749-56. PubMed ID: 14519709
[TBL] [Abstract][Full Text] [Related]
8. Long-term azitromycin treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection; an observational cohort study.
Hansen CR; Pressler T; Koch C; Høiby N
J Cyst Fibros; 2005 Mar; 4(1):35-40. PubMed ID: 15752679
[TBL] [Abstract][Full Text] [Related]
9. Low-dose inhaled budesonide once or twice daily for 27 months in children with mild asthma.
Jónasson G; Carlsen KH; Jonasson C; Mowinckel P
Allergy; 2000 Aug; 55(8):740-8. PubMed ID: 10955700
[TBL] [Abstract][Full Text] [Related]
10. A formulation of aerosolized tobramycin (Bramitob) in the treatment of patients with cystic fibrosis and Pseudomonas aeruginosa infection: a double-blind, placebo-controlled, multicenter study.
Chuchalin A; Csiszér E; Gyurkovics K; Bartnicka MT; Sands D; Kapranov N; Varoli G; Monici Preti PA; Mazurek H
Paediatr Drugs; 2007; 9 Suppl 1():21-31. PubMed ID: 17536872
[TBL] [Abstract][Full Text] [Related]
11. A 12-week, multicenter, randomized, partially blinded, active-controlled, parallel-group study of budesonide inhalation suspension in adolescents and adults with moderate to severe persistent asthma previously receiving inhaled corticosteroids with a metered-dose or dry powder inhaler.
Murphy K; Noonan M; Silkoff PE; Uryniak T
Clin Ther; 2007 Jun; 29(6):1013-26. PubMed ID: 17692718
[TBL] [Abstract][Full Text] [Related]
12. Budesonide delivered by Turbuhaler is effective in a dose-dependent fashion when used in the treatment of adult patients with chronic asthma.
Busse WW; Chervinsky P; Condemi J; Lumry WR; Petty TL; Rennard S; Townley RG
J Allergy Clin Immunol; 1998 Apr; 101(4 Pt 1):457-63. PubMed ID: 9564797
[TBL] [Abstract][Full Text] [Related]
13. Dose-response comparison of budesonide dry powder inhalers using adenosine monophosphate bronchial challenge.
Lipworth BJ; Sims EJ; Das SK; Buck H; Paterson M
Ann Allergy Asthma Immunol; 2005 Jun; 94(6):675-81. PubMed ID: 15984601
[TBL] [Abstract][Full Text] [Related]
14. Comparison of Inhaled Antibiotics for the Treatment of Chronic Pseudomonas aeruginosa Lung Infection in Patients With Cystic Fibrosis: Systematic Literature Review and Network Meta-analysis.
Elborn JS; Vataire AL; Fukushima A; Aballea S; Khemiri A; Moore C; Medic G; Hemels ME
Clin Ther; 2016 Oct; 38(10):2204-2226. PubMed ID: 27692977
[TBL] [Abstract][Full Text] [Related]
15. Tobramycin inhalation powder in cystic fibrosis patients: response by age group.
Geller DE; Nasr SZ; Piggott S; He E; Angyalosi G; Higgins M
Respir Care; 2014 Mar; 59(3):388-98. PubMed ID: 23983274
[TBL] [Abstract][Full Text] [Related]
16. Efficacy, safety, and local pharmacokinetics of highly concentrated nebulized tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa.
Lenoir G; Antypkin YG; Miano A; Moretti P; Zanda M; Varoli G; Monici Preti PA; Aryayev NL
Paediatr Drugs; 2007; 9 Suppl 1():11-20. PubMed ID: 17536871
[TBL] [Abstract][Full Text] [Related]
17. Tolerability and pharmacokinetic properties of ciprofloxacin dry powder for inhalation in patients with cystic fibrosis: a phase I, randomized, dose-escalation study.
Stass H; Weimann B; Nagelschmitz J; Rolinck-Werninghaus C; Staab D
Clin Ther; 2013 Oct; 35(10):1571-81. PubMed ID: 24054830
[TBL] [Abstract][Full Text] [Related]
18. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial.
Vestbo J; Sørensen T; Lange P; Brix A; Torre P; Viskum K
Lancet; 1999 May; 353(9167):1819-23. PubMed ID: 10359405
[TBL] [Abstract][Full Text] [Related]
19. A phase 3, multi-center, multinational, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of levofloxacin inhalation solution (APT-1026) in stable cystic fibrosis patients.
Flume PA; VanDevanter DR; Morgan EE; Dudley MN; Loutit JS; Bell SC; Kerem E; Fischer R; Smyth AR; Aaron SD; Conrad D; Geller DE; Elborn JS
J Cyst Fibros; 2016 Jul; 15(4):495-502. PubMed ID: 26852040
[TBL] [Abstract][Full Text] [Related]
20. Differences in prevalence and treatment of Pseudomonas aeruginosa in cystic fibrosis centres in Denmark, Norway and Sweden.
Knudsen PK; Olesen HV; Høiby N; Johannesson M; Karpati F; Laerum BN; Meyer P; Pressler T; Lindblad A;
J Cyst Fibros; 2009 Mar; 8(2):135-42. PubMed ID: 19157995
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
